GoodRx (GDRX) Scheduled to Post Quarterly Earnings on Thursday

GoodRx (NASDAQ:GDRX) is scheduled to be announcing its earnings results before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of $0.09 per share for the quarter. GoodRx has set its Q1 2024 guidance at EPS and its FY 2024 guidance at EPS.Parties that are interested in registering for the company’s conference call can do so using this link.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Thursday, February 29th. The company reported $0.02 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.02. The firm had revenue of $196.64 million for the quarter, compared to analyst estimates of $195.59 million. GoodRx had a negative net margin of 1.18% and a positive return on equity of 2.45%. On average, analysts expect GoodRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

GoodRx Trading Up 5.2 %

Shares of GDRX opened at $7.47 on Tuesday. The firm’s 50-day moving average price is $6.99 and its 200-day moving average price is $6.34. The firm has a market capitalization of $2.95 billion, a price-to-earnings ratio of -373.50, a PEG ratio of 3.89 and a beta of 1.37. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 0.85. GoodRx has a 1-year low of $4.14 and a 1-year high of $9.37.

Analyst Ratings Changes

GDRX has been the topic of several research reports. Barclays boosted their price objective on shares of GoodRx from $8.00 to $9.00 and gave the stock an “overweight” rating in a research note on Friday, March 1st. Wells Fargo & Company raised shares of GoodRx from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $7.50 to $10.00 in a report on Monday, March 25th. JPMorgan Chase & Co. raised shares of GoodRx from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $7.00 to $10.00 in a report on Friday, March 1st. UBS Group lifted their target price on shares of GoodRx from $5.00 to $8.00 and gave the stock a “neutral” rating in a report on Friday, March 1st. Finally, Truist Financial lifted their target price on shares of GoodRx from $7.50 to $8.00 and gave the stock a “hold” rating in a report on Friday, March 1st. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $8.78.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.